Recently, the USFood and Drug Administration (FDA) approved tolvaptan as the f i rst drug treatment toslowkidneyfunctiondeclineinadultsatriskofrapidlyprogressingADPKD.Fullprescribinginformation approvedbythe FDAprovides helpfulguidelinesbutdoes notaddress prac-ticalquestionsthatarebeingraisedbynephrologists,...
Liver function tests are mandated prior to the initiation of tolvaptan and monthly for 18 months then 3 monthly after that. This is based on the finding of the REPRISE trial that nearly all cases of treatment-associated liver abnormalities occurred within the first 18 months [24]. Advice on m...
Patients were collected in a period of seven years; all the examined subjects gave their written informed consent for genetic testing, data treatment and storage, approved by the Institutional Quality Assessment committee. All the methods were performed in accordance with the guidelines and the ...
Sequencing for monoallelic NEK8 variants in patients with childhood and early-adulthood cystic kidney disease can inform renal prognosis, treatment planning, familial screening and reproductive choices.Table 1: Clinical and genetic description of families with monoallelic NEK8-related ADPKD....
patients with ADPKD. In addition, it might be clinically relevant to analyze the performance of both techniques for predicting the disease’s progression and identifying patients at risk of experiencing accelerated disease progression, which facilitates customized monitoring and tailored treatment strategies....
The available antimicrobial treatment guidelines, therefore, might not be appropriate to some patients.doi:10.1186/s12879-019-4444-yLaura OnuchicVictor Augusto Hamamoto SatoPrecil Diego Miranda de Menezes NevesBruno Eduardo Pedroso BalboAntnio Abel Portela-Neto...
When balancing the pros and cons of treatment, a treatment with a high cost or therapeutic burden may still be worthwhile in the context of high risk and opportunity for significant benefit. The Mayo classification has subsequently been included in clinical practice guidelines from around the world...
The management of abnormal LFTs detected during tolvaptan treatment should be conducted according to local regulatory guidelines and product information (Figure 7). The administration of tolvaptan should be held, other possible etiologies considered, and LFTs rechecked within 48–72 hours if an elevation...
The management of abnormal LFTs detected during tolvaptan treatment should be conducted according to local regulatory guidelines and product information (Figure 7). The administration of tolvaptan should be held, other possible etiologies considered, and LFTs rechecked within 48–72 hours if an elevation...
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary Kidney International, Volume 107, Issue 2, February 2025, Pages 234-254 Vicente E. Torres, Curie Ahn, Thijs R.M. Barten, Godela Brosnahan...